N/A N=33 Role of Peanuts in Healthy Weight Gain in Athletic Individuals
Weight Gain
Primary: Change in Total Body Mass (Weight) — 1.6; 2.7; 1.8; 2.2 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=92 Evaluation of the Efficacy in Decreasing Myopia Progression of the Proposed Ophthalmic Lens Prototypes
Myopia
Primary: Axial Lenght Increase — 0.27; 0.37 mm
N/A N=76 A Comparative Analysis of Hypocalcemia Incidence in Patients Undergoing Thyroidectomy: Ligasure vs Conventional Ligation of Vessels by Knot Tying
Hypocalcemia After Total Thyroidectomy · Hypocalcemia
Primary: Number of Participants With Hypocalcemia — 4; 3 participants
N/A N=242 Dietary Recommendations for Reducing Free Sugar Intakes
Dietary Recommendations
Primary: Free Sugar Intakes — 7.7; 7.4; 7.1; 9.2 percentage of total energy intake
N/A N=57 Protective Stepping in People With MS
Multiple Sclerosis
Primary: Training-related Change in Margin of Stability — 0.0289; 0.0217 meters — p=0.036
N/A N=44 Transcranial Direct Current Stimulation for Post-stroke Gait Rehab
Stroke · Gait Impairment
Primary: Change in Gait Speed From Baseline (Meters/Second) — 0.16; 0.12 meters/second
Phase 3 N=141 Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia - Heterozygous
Primary: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) — -27.14; 1.40 percent change in LDL-C — p=<.0001
N/A N=26 Oxalobacter Formigenes Colonization and Urinary Oxalate Excretion
Calcium Oxalate Urolithiasis
Primary: Percent Decrease in Urinary Oxalate Excretion After Colonization With O.Formigenes — 14 Percentage decrease in urinary oxalate
N/A N=16 Powered Orthotic Exoskeleton Training in Stroke
Stroke
Primary: Five Times Sit to Stand Test (5xSTS) — -20.3; -10.9; -9.3 seconds — p==0.007
Phase 1 N=34 Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Prolymphocytic Leukemia · Recurrent Adult Diffuse Large Cell Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose for Selinexor — 40 mg
Phase 4 N=100 Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
Atrial Fibrillation · Device Related Thrombus · Left Atrial Appendage Thrombosis
Primary: Device Related Thrombus (DRT) at 90 Days — 1 Participants
N/A N=16 Five Session Unified Protocol for Older Adults With Emotional Distress and Reduced Mobility
Emotional Distress · Anxiety · Depression
Primary: Client Satisfaction Questionnaire (CSQ) — 30.5; 23.38; 30.88; 25.25 score on a scale — p=.03
N/A N=30 Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors
Breast Cancer
Primary: Study Attrition and Adherence — 1; 1; 14; 14 Participants
Phase 3 N=15 Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)
Tricuspid Regurgitation
Primary: Procedural Success — 42.86 Percentage of Participants
Phase 2 N=91 Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery
Inflammation
Primary: Anterior Chamber Cell: Categorical Cure — 18; 16; 6 Participants